Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

2018 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2018 Round 2 Seed Funding Grants. The Wesfarmers Centre Scientific

2018 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2016 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.

News & Events

RSV responsible for one out of every 50 childhood deaths worldwide

The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.

Research

Mosaic Darier disease flaring following allogeneic stem cell transplant

Bernadette Ricciardo MBBS (hon) DCH FACD PhD Candidate Bernadette.Ricciardo@telethonkids.org.au PhD Candidate Dr Bernadette Ricciardo is a PhD

Research

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13. 

News & Events

Help us build a new weapon in the fight against deadly flu

At just two years old, Lucy lost her fight against flu. With your generous help, we can finally beat influenza.

News & Events

Study confirms maternal whooping cough vaccine protects babies at critical age

A The Kids Research Institute Australia and Curtin University-led study has found the maternal whooping cough vaccine given to pregnant mothers in the second or third trimester significantly reduced babies’ risk of infection, protecting them at their most vulnerable age.

The PRIME Study

Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.

FluBub Study

The FluBub Study aims to learn more about the safety and effectiveness of giving the influenza vaccine to younger babies and providing them with much-needed protection earlier in life.